nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CYP2D6—Gefitinib—lung cancer	0.0621	0.125	CbGbCtD
Darifenacin—CYP2D6—Vinorelbine—lung cancer	0.0478	0.096	CbGbCtD
Darifenacin—CYP3A4—Topotecan—lung cancer	0.0431	0.0867	CbGbCtD
Darifenacin—CYP3A4—Gefitinib—lung cancer	0.0395	0.0793	CbGbCtD
Darifenacin—CYP3A4—Teniposide—lung cancer	0.0383	0.0769	CbGbCtD
Darifenacin—CYP2D6—Erlotinib—lung cancer	0.0367	0.0737	CbGbCtD
Darifenacin—CYP3A4—Vinorelbine—lung cancer	0.0304	0.0611	CbGbCtD
Darifenacin—CYP2D6—Vinblastine—lung cancer	0.0295	0.0592	CbGbCtD
Darifenacin—CYP3A4—Crizotinib—lung cancer	0.0242	0.0486	CbGbCtD
Darifenacin—CYP3A4—Erlotinib—lung cancer	0.0233	0.0469	CbGbCtD
Darifenacin—CYP3A4—Paclitaxel—lung cancer	0.0214	0.0429	CbGbCtD
Darifenacin—CYP3A4—Irinotecan—lung cancer	0.0211	0.0423	CbGbCtD
Darifenacin—CYP3A4—Vinblastine—lung cancer	0.0187	0.0376	CbGbCtD
Darifenacin—CYP2D6—Doxorubicin—lung cancer	0.0181	0.0364	CbGbCtD
Darifenacin—CYP3A4—Etoposide—lung cancer	0.0169	0.0339	CbGbCtD
Darifenacin—CYP3A4—Docetaxel—lung cancer	0.0154	0.031	CbGbCtD
Darifenacin—CYP3A4—Doxorubicin—lung cancer	0.0115	0.0231	CbGbCtD
Darifenacin—Loperamide—POMC—lung cancer	0.00212	0.329	CrCbGaD
Darifenacin—Clotrimazole—ABCC3—lung cancer	0.00152	0.235	CrCbGaD
Darifenacin—Clotrimazole—CYP2A6—lung cancer	0.000823	0.128	CrCbGaD
Darifenacin—Clotrimazole—CYP2E1—lung cancer	0.000584	0.0908	CrCbGaD
Darifenacin—Fexofenadine—ABCB1—lung cancer	0.000396	0.0616	CrCbGaD
Darifenacin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000341	0.000899	CcSEcCtD
Darifenacin—Confusional state—Etoposide—lung cancer	0.00034	0.000896	CcSEcCtD
Darifenacin—Pain—Gemcitabine—lung cancer	0.000338	0.00089	CcSEcCtD
Darifenacin—Constipation—Gemcitabine—lung cancer	0.000338	0.00089	CcSEcCtD
Darifenacin—Nausea—Erlotinib—lung cancer	0.000338	0.00089	CcSEcCtD
Darifenacin—Dry mouth—Paclitaxel—lung cancer	0.000337	0.000889	CcSEcCtD
Darifenacin—Anaphylactic shock—Etoposide—lung cancer	0.000337	0.000889	CcSEcCtD
Darifenacin—Diarrhoea—Vinorelbine—lung cancer	0.000336	0.000887	CcSEcCtD
Darifenacin—Dysgeusia—Docetaxel—lung cancer	0.000336	0.000886	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000335	0.000884	CcSEcCtD
Darifenacin—Infection—Etoposide—lung cancer	0.000335	0.000883	CcSEcCtD
Darifenacin—Feeling abnormal—Irinotecan—lung cancer	0.000334	0.000881	CcSEcCtD
Darifenacin—Confusional state—Paclitaxel—lung cancer	0.000334	0.000879	CcSEcCtD
Darifenacin—Back pain—Docetaxel—lung cancer	0.000332	0.000876	CcSEcCtD
Darifenacin—Gastrointestinal pain—Irinotecan—lung cancer	0.000332	0.000874	CcSEcCtD
Darifenacin—Anaphylactic shock—Paclitaxel—lung cancer	0.000331	0.000872	CcSEcCtD
Darifenacin—Oedema—Paclitaxel—lung cancer	0.000331	0.000872	CcSEcCtD
Darifenacin—Tachycardia—Etoposide—lung cancer	0.000329	0.000868	CcSEcCtD
Darifenacin—Infection—Paclitaxel—lung cancer	0.000329	0.000866	CcSEcCtD
Darifenacin—Dyspnoea—Cisplatin—lung cancer	0.000328	0.000865	CcSEcCtD
Darifenacin—Skin disorder—Etoposide—lung cancer	0.000328	0.000863	CcSEcCtD
Darifenacin—Erectile dysfunction—Methotrexate—lung cancer	0.000327	0.000862	CcSEcCtD
Darifenacin—Dry skin—Doxorubicin—lung cancer	0.000326	0.00086	CcSEcCtD
Darifenacin—Hyperhidrosis—Etoposide—lung cancer	0.000326	0.000859	CcSEcCtD
Darifenacin—Feeling abnormal—Gemcitabine—lung cancer	0.000326	0.000858	CcSEcCtD
Darifenacin—Shock—Paclitaxel—lung cancer	0.000325	0.000857	CcSEcCtD
Darifenacin—Dizziness—Vinorelbine—lung cancer	0.000325	0.000857	CcSEcCtD
Darifenacin—Nervous system disorder—Paclitaxel—lung cancer	0.000324	0.000855	CcSEcCtD
Darifenacin—Tachycardia—Paclitaxel—lung cancer	0.000323	0.000851	CcSEcCtD
Darifenacin—Breast disorder—Doxorubicin—lung cancer	0.000322	0.000848	CcSEcCtD
Darifenacin—Skin disorder—Paclitaxel—lung cancer	0.000321	0.000847	CcSEcCtD
Darifenacin—Abdominal pain—Irinotecan—lung cancer	0.000321	0.000845	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.000321	0.000845	CcSEcCtD
Darifenacin—Hyperhidrosis—Paclitaxel—lung cancer	0.00032	0.000843	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Cisplatin—lung cancer	0.000318	0.000838	CcSEcCtD
Darifenacin—Infestation NOS—Methotrexate—lung cancer	0.000317	0.000835	CcSEcCtD
Darifenacin—Infestation—Methotrexate—lung cancer	0.000317	0.000835	CcSEcCtD
Darifenacin—Pain—Cisplatin—lung cancer	0.000315	0.00083	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000314	0.000827	CcSEcCtD
Darifenacin—Vomiting—Vinorelbine—lung cancer	0.000313	0.000824	CcSEcCtD
Darifenacin—Rash—Vinorelbine—lung cancer	0.00031	0.000817	CcSEcCtD
Darifenacin—Dermatitis—Vinorelbine—lung cancer	0.00031	0.000816	CcSEcCtD
Darifenacin—Stomatitis—Methotrexate—lung cancer	0.000309	0.000814	CcSEcCtD
Darifenacin—Headache—Vinorelbine—lung cancer	0.000308	0.000812	CcSEcCtD
Darifenacin—Syncope—Docetaxel—lung cancer	0.000308	0.000812	CcSEcCtD
Darifenacin—Influenza—Doxorubicin—lung cancer	0.000308	0.000811	CcSEcCtD
Darifenacin—Clotrimazole—ABCB1—lung cancer	0.000306	0.0476	CrCbGaD
Darifenacin—Sweating—Methotrexate—lung cancer	0.000304	0.0008	CcSEcCtD
Darifenacin—Palpitations—Docetaxel—lung cancer	0.000304	0.0008	CcSEcCtD
Darifenacin—Feeling abnormal—Cisplatin—lung cancer	0.000303	0.0008	CcSEcCtD
Darifenacin—Loss of consciousness—Docetaxel—lung cancer	0.000302	0.000796	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000301	0.000794	CcSEcCtD
Darifenacin—Dyspnoea—Etoposide—lung cancer	0.000301	0.000793	CcSEcCtD
Darifenacin—Somnolence—Etoposide—lung cancer	0.0003	0.00079	CcSEcCtD
Darifenacin—Cough—Docetaxel—lung cancer	0.0003	0.00079	CcSEcCtD
Darifenacin—Insomnia—Paclitaxel—lung cancer	0.000299	0.000788	CcSEcCtD
Darifenacin—Hypersensitivity—Irinotecan—lung cancer	0.000299	0.000787	CcSEcCtD
Darifenacin—Hypertension—Docetaxel—lung cancer	0.000297	0.000781	CcSEcCtD
Darifenacin—Bronchitis—Doxorubicin—lung cancer	0.000296	0.00078	CcSEcCtD
Darifenacin—Dyspnoea—Paclitaxel—lung cancer	0.000295	0.000777	CcSEcCtD
Darifenacin—Somnolence—Paclitaxel—lung cancer	0.000294	0.000775	CcSEcCtD
Darifenacin—Arthralgia—Docetaxel—lung cancer	0.000292	0.000771	CcSEcCtD
Darifenacin—Nausea—Vinorelbine—lung cancer	0.000292	0.00077	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Etoposide—lung cancer	0.000291	0.000767	CcSEcCtD
Darifenacin—Dyspepsia—Paclitaxel—lung cancer	0.000291	0.000767	CcSEcCtD
Darifenacin—Asthenia—Irinotecan—lung cancer	0.000291	0.000767	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.00029	0.000765	CcSEcCtD
Darifenacin—Constipation—Etoposide—lung cancer	0.000288	0.00076	CcSEcCtD
Darifenacin—Pain—Etoposide—lung cancer	0.000288	0.00076	CcSEcCtD
Darifenacin—Dry mouth—Docetaxel—lung cancer	0.000286	0.000754	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000286	0.000752	CcSEcCtD
Darifenacin—Asthenia—Gemcitabine—lung cancer	0.000283	0.000747	CcSEcCtD
Darifenacin—Pain—Paclitaxel—lung cancer	0.000283	0.000745	CcSEcCtD
Darifenacin—Constipation—Paclitaxel—lung cancer	0.000283	0.000745	CcSEcCtD
Darifenacin—Confusional state—Docetaxel—lung cancer	0.000283	0.000745	CcSEcCtD
Darifenacin—Pharyngitis—Methotrexate—lung cancer	0.000282	0.000744	CcSEcCtD
Darifenacin—Urinary tract disorder—Methotrexate—lung cancer	0.000281	0.00074	CcSEcCtD
Darifenacin—Anaphylactic shock—Docetaxel—lung cancer	0.00028	0.000739	CcSEcCtD
Darifenacin—Oedema—Docetaxel—lung cancer	0.00028	0.000739	CcSEcCtD
Darifenacin—Weight increased—Doxorubicin—lung cancer	0.00028	0.000738	CcSEcCtD
Darifenacin—Pruritus—Gemcitabine—lung cancer	0.00028	0.000737	CcSEcCtD
Darifenacin—Urethral disorder—Methotrexate—lung cancer	0.000279	0.000735	CcSEcCtD
Darifenacin—Infection—Docetaxel—lung cancer	0.000279	0.000734	CcSEcCtD
Darifenacin—Feeling abnormal—Etoposide—lung cancer	0.000278	0.000733	CcSEcCtD
Darifenacin—Diarrhoea—Irinotecan—lung cancer	0.000277	0.000731	CcSEcCtD
Darifenacin—Gastrointestinal pain—Etoposide—lung cancer	0.000276	0.000727	CcSEcCtD
Darifenacin—Shock—Docetaxel—lung cancer	0.000276	0.000727	CcSEcCtD
Darifenacin—Nervous system disorder—Docetaxel—lung cancer	0.000275	0.000724	CcSEcCtD
Darifenacin—Infestation NOS—Doxorubicin—lung cancer	0.000274	0.000723	CcSEcCtD
Darifenacin—Infestation—Doxorubicin—lung cancer	0.000274	0.000723	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—lung cancer	0.000274	0.000722	CcSEcCtD
Darifenacin—Tachycardia—Docetaxel—lung cancer	0.000274	0.000721	CcSEcCtD
Darifenacin—Feeling abnormal—Paclitaxel—lung cancer	0.000273	0.000718	CcSEcCtD
Darifenacin—Skin disorder—Docetaxel—lung cancer	0.000272	0.000718	CcSEcCtD
Darifenacin—Hypersensitivity—Cisplatin—lung cancer	0.000271	0.000715	CcSEcCtD
Darifenacin—Gastrointestinal pain—Paclitaxel—lung cancer	0.00027	0.000713	CcSEcCtD
Darifenacin—Diarrhoea—Gemcitabine—lung cancer	0.00027	0.000712	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—lung cancer	0.000269	0.000709	CcSEcCtD
Darifenacin—Dizziness—Irinotecan—lung cancer	0.000268	0.000707	CcSEcCtD
Darifenacin—Stomatitis—Doxorubicin—lung cancer	0.000267	0.000705	CcSEcCtD
Darifenacin—Abdominal pain—Etoposide—lung cancer	0.000267	0.000703	CcSEcCtD
Darifenacin—Urinary tract infection—Doxorubicin—lung cancer	0.000267	0.000703	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—lung cancer	0.000266	0.0007	CcSEcCtD
Darifenacin—Asthenia—Cisplatin—lung cancer	0.000264	0.000696	CcSEcCtD
Darifenacin—Sweating—Doxorubicin—lung cancer	0.000263	0.000693	CcSEcCtD
Darifenacin—Fentanyl—ABCB1—lung cancer	0.000262	0.0407	CrCbGaD
Darifenacin—Abdominal pain—Paclitaxel—lung cancer	0.000261	0.000689	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—lung cancer	0.000258	0.00068	CcSEcCtD
Darifenacin—Vomiting—Irinotecan—lung cancer	0.000258	0.000679	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—lung cancer	0.000257	0.000678	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—lung cancer	0.000256	0.000675	CcSEcCtD
Darifenacin—Rash—Irinotecan—lung cancer	0.000256	0.000674	CcSEcCtD
Darifenacin—Dermatitis—Irinotecan—lung cancer	0.000255	0.000673	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000255	0.000673	CcSEcCtD
Darifenacin—Headache—Irinotecan—lung cancer	0.000254	0.000669	CcSEcCtD
Darifenacin—Insomnia—Docetaxel—lung cancer	0.000254	0.000668	CcSEcCtD
Darifenacin—Loperamide—ABCB1—lung cancer	0.000252	0.0392	CrCbGaD
Darifenacin—Diarrhoea—Cisplatin—lung cancer	0.000252	0.000664	CcSEcCtD
Darifenacin—Vomiting—Gemcitabine—lung cancer	0.000251	0.000662	CcSEcCtD
Darifenacin—Dyspnoea—Docetaxel—lung cancer	0.00025	0.000659	CcSEcCtD
Darifenacin—Somnolence—Docetaxel—lung cancer	0.000249	0.000657	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—lung cancer	0.000249	0.000657	CcSEcCtD
Darifenacin—Rash—Gemcitabine—lung cancer	0.000249	0.000656	CcSEcCtD
Darifenacin—Dermatitis—Gemcitabine—lung cancer	0.000249	0.000656	CcSEcCtD
Darifenacin—Hypersensitivity—Etoposide—lung cancer	0.000249	0.000655	CcSEcCtD
Darifenacin—Headache—Gemcitabine—lung cancer	0.000247	0.000652	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—lung cancer	0.000247	0.000651	CcSEcCtD
Darifenacin—Dyspepsia—Docetaxel—lung cancer	0.000247	0.00065	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—lung cancer	0.000244	0.000644	CcSEcCtD
Darifenacin—Hypersensitivity—Paclitaxel—lung cancer	0.000244	0.000642	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—lung cancer	0.000243	0.000641	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—lung cancer	0.000243	0.000639	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—lung cancer	0.000242	0.000639	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Docetaxel—lung cancer	0.000242	0.000638	CcSEcCtD
Darifenacin—Asthenia—Etoposide—lung cancer	0.000242	0.000638	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—lung cancer	0.000241	0.000636	CcSEcCtD
Darifenacin—Nausea—Irinotecan—lung cancer	0.000241	0.000635	CcSEcCtD
Darifenacin—Pain—Docetaxel—lung cancer	0.00024	0.000632	CcSEcCtD
Darifenacin—Constipation—Docetaxel—lung cancer	0.00024	0.000632	CcSEcCtD
Darifenacin—Back pain—Methotrexate—lung cancer	0.000239	0.000631	CcSEcCtD
Darifenacin—Pruritus—Etoposide—lung cancer	0.000239	0.000629	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—lung cancer	0.000237	0.000625	CcSEcCtD
Darifenacin—Asthenia—Paclitaxel—lung cancer	0.000237	0.000625	CcSEcCtD
Darifenacin—Nausea—Gemcitabine—lung cancer	0.000235	0.000618	CcSEcCtD
Darifenacin—Vomiting—Cisplatin—lung cancer	0.000234	0.000617	CcSEcCtD
Darifenacin—Pruritus—Paclitaxel—lung cancer	0.000234	0.000617	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—lung cancer	0.000233	0.000615	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—lung cancer	0.000233	0.000614	CcSEcCtD
Darifenacin—Rash—Cisplatin—lung cancer	0.000232	0.000612	CcSEcCtD
Darifenacin—Dermatitis—Cisplatin—lung cancer	0.000232	0.000611	CcSEcCtD
Darifenacin—Feeling abnormal—Docetaxel—lung cancer	0.000231	0.000609	CcSEcCtD
Darifenacin—Diarrhoea—Etoposide—lung cancer	0.000231	0.000608	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—lung cancer	0.00023	0.000606	CcSEcCtD
Darifenacin—Gastrointestinal pain—Docetaxel—lung cancer	0.000229	0.000604	CcSEcCtD
Darifenacin—Diarrhoea—Paclitaxel—lung cancer	0.000226	0.000596	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—lung cancer	0.000223	0.000589	CcSEcCtD
Darifenacin—Dizziness—Etoposide—lung cancer	0.000223	0.000588	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—lung cancer	0.000222	0.000585	CcSEcCtD
Darifenacin—Abdominal pain—Docetaxel—lung cancer	0.000222	0.000584	CcSEcCtD
Darifenacin—Dizziness—Paclitaxel—lung cancer	0.000219	0.000576	CcSEcCtD
Darifenacin—Nausea—Cisplatin—lung cancer	0.000219	0.000576	CcSEcCtD
Darifenacin—Cough—Methotrexate—lung cancer	0.000216	0.000569	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—lung cancer	0.000216	0.000569	CcSEcCtD
Darifenacin—Vomiting—Etoposide—lung cancer	0.000214	0.000565	CcSEcCtD
Darifenacin—Rash—Etoposide—lung cancer	0.000213	0.00056	CcSEcCtD
Darifenacin—Dermatitis—Etoposide—lung cancer	0.000213	0.00056	CcSEcCtD
Darifenacin—Headache—Etoposide—lung cancer	0.000211	0.000557	CcSEcCtD
Darifenacin—Flatulence—Doxorubicin—lung cancer	0.000211	0.000557	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—lung cancer	0.000211	0.000555	CcSEcCtD
Darifenacin—Vomiting—Paclitaxel—lung cancer	0.00021	0.000554	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—lung cancer	0.00021	0.000553	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000209	0.000552	CcSEcCtD
Darifenacin—Rash—Paclitaxel—lung cancer	0.000209	0.00055	CcSEcCtD
Darifenacin—Dermatitis—Paclitaxel—lung cancer	0.000208	0.000549	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—lung cancer	0.000207	0.000546	CcSEcCtD
Darifenacin—Headache—Paclitaxel—lung cancer	0.000207	0.000546	CcSEcCtD
Darifenacin—Hypersensitivity—Docetaxel—lung cancer	0.000207	0.000544	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—lung cancer	0.000204	0.000537	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—lung cancer	0.000202	0.000532	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—lung cancer	0.000202	0.000532	CcSEcCtD
Darifenacin—Asthenia—Docetaxel—lung cancer	0.000201	0.00053	CcSEcCtD
Darifenacin—Infection—Methotrexate—lung cancer	0.000201	0.000529	CcSEcCtD
Darifenacin—Nausea—Etoposide—lung cancer	0.0002	0.000528	CcSEcCtD
Darifenacin—Pruritus—Docetaxel—lung cancer	0.000198	0.000523	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—lung cancer	0.000198	0.000522	CcSEcCtD
Darifenacin—Nausea—Paclitaxel—lung cancer	0.000196	0.000518	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—lung cancer	0.000196	0.000517	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—lung cancer	0.000195	0.000515	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—lung cancer	0.000192	0.000507	CcSEcCtD
Darifenacin—Diarrhoea—Docetaxel—lung cancer	0.000192	0.000505	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—lung cancer	0.000189	0.000499	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—lung cancer	0.000188	0.000497	CcSEcCtD
Darifenacin—Cough—Doxorubicin—lung cancer	0.000187	0.000493	CcSEcCtD
Darifenacin—Dizziness—Docetaxel—lung cancer	0.000185	0.000489	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—lung cancer	0.000185	0.000488	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000184	0.000485	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—lung cancer	0.000183	0.000482	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—lung cancer	0.000183	0.000481	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000181	0.000478	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—lung cancer	0.00018	0.000475	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—lung cancer	0.00018	0.000473	CcSEcCtD
Darifenacin—Methadone—ABCB1—lung cancer	0.00018	0.0279	CrCbGaD
Darifenacin—Dry mouth—Doxorubicin—lung cancer	0.000179	0.00047	CcSEcCtD
Darifenacin—Vomiting—Docetaxel—lung cancer	0.000178	0.00047	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—lung cancer	0.000178	0.000469	CcSEcCtD
Darifenacin—Rash—Docetaxel—lung cancer	0.000177	0.000466	CcSEcCtD
Darifenacin—Dermatitis—Docetaxel—lung cancer	0.000177	0.000465	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—lung cancer	0.000176	0.000465	CcSEcCtD
Darifenacin—Headache—Docetaxel—lung cancer	0.000176	0.000463	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—lung cancer	0.000175	0.000461	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—lung cancer	0.000175	0.000461	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—lung cancer	0.000174	0.00046	CcSEcCtD
Darifenacin—Infection—Doxorubicin—lung cancer	0.000174	0.000458	CcSEcCtD
Darifenacin—Pain—Methotrexate—lung cancer	0.000173	0.000455	CcSEcCtD
Darifenacin—Shock—Doxorubicin—lung cancer	0.000172	0.000454	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—lung cancer	0.000172	0.000452	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—lung cancer	0.000171	0.00045	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—lung cancer	0.00017	0.000448	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—lung cancer	0.000169	0.000446	CcSEcCtD
Darifenacin—Nausea—Docetaxel—lung cancer	0.000167	0.000439	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—lung cancer	0.000167	0.000439	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—lung cancer	0.000165	0.000435	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—lung cancer	0.00016	0.000421	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000159	0.00042	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—lung cancer	0.000158	0.000417	CcSEcCtD
Darifenacin—Dyspnoea—Doxorubicin—lung cancer	0.000156	0.000411	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—lung cancer	0.000156	0.00041	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—lung cancer	0.000154	0.000406	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000151	0.000398	CcSEcCtD
Darifenacin—Pain—Doxorubicin—lung cancer	0.00015	0.000394	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—lung cancer	0.00015	0.000394	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—lung cancer	0.000149	0.000392	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—lung cancer	0.000145	0.000382	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—lung cancer	0.000144	0.00038	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—lung cancer	0.000143	0.000377	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—lung cancer	0.000143	0.000377	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—lung cancer	0.000138	0.000364	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—lung cancer	0.000138	0.000364	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—lung cancer	0.000134	0.000352	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—lung cancer	0.000129	0.00034	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—lung cancer	0.000128	0.000339	CcSEcCtD
Darifenacin—Rash—Methotrexate—lung cancer	0.000127	0.000336	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—lung cancer	0.000127	0.000335	CcSEcCtD
Darifenacin—Headache—Methotrexate—lung cancer	0.000127	0.000334	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—lung cancer	0.000126	0.000331	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—lung cancer	0.000124	0.000326	CcSEcCtD
Darifenacin—Nausea—Methotrexate—lung cancer	0.00012	0.000316	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—lung cancer	0.00012	0.000315	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—lung cancer	0.000116	0.000305	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—lung cancer	0.000111	0.000293	CcSEcCtD
Darifenacin—Rash—Doxorubicin—lung cancer	0.00011	0.000291	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—lung cancer	0.00011	0.00029	CcSEcCtD
Darifenacin—Headache—Doxorubicin—lung cancer	0.00011	0.000289	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—lung cancer	0.000104	0.000274	CcSEcCtD
Darifenacin—CYP3A4—Metabolism—NCOA3—lung cancer	1.46e-05	0.000126	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AKT1—lung cancer	1.45e-05	0.000125	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CD—lung cancer	1.44e-05	0.000124	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCL8—lung cancer	1.44e-05	0.000124	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CASP3—lung cancer	1.44e-05	0.000124	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTP1—lung cancer	1.43e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL2—lung cancer	1.43e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—HRAS—lung cancer	1.43e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL6—lung cancer	1.43e-05	0.000123	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ADCY1—lung cancer	1.42e-05	0.000122	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCG2—lung cancer	1.42e-05	0.000122	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALB—lung cancer	1.42e-05	0.000122	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCND1—lung cancer	1.4e-05	0.00012	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CAT—lung cancer	1.4e-05	0.00012	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ENO2—lung cancer	1.4e-05	0.00012	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HPGDS—lung cancer	1.4e-05	0.00012	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—JUN—lung cancer	1.39e-05	0.00012	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AKT1—lung cancer	1.39e-05	0.000119	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.39e-05	0.000119	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CASP3—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CG—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APC—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KIT—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—NRAS—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL2—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APC—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KIT—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CG—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—NRAS—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—lung cancer	1.37e-05	0.000118	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ABCB1—lung cancer	1.36e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGF—lung cancer	1.36e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—lung cancer	1.36e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CG—lung cancer	1.36e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APC—lung cancer	1.36e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KIT—lung cancer	1.36e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—NRAS—lung cancer	1.36e-05	0.000117	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTT1—lung cancer	1.35e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGF—lung cancer	1.35e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CDKN1A—lung cancer	1.35e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PTEN—lung cancer	1.35e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGF—lung cancer	1.34e-05	0.000115	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCND1—lung cancer	1.34e-05	0.000115	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GCLC—lung cancer	1.34e-05	0.000115	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP2A6—lung cancer	1.34e-05	0.000115	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—JUN—lung cancer	1.34e-05	0.000115	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—TYMS—lung cancer	1.33e-05	0.000115	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTM1—lung cancer	1.32e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AKT1—lung cancer	1.32e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—MAPK3—lung cancer	1.32e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—MAPK3—lung cancer	1.31e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—POMC—lung cancer	1.31e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—POMC—lung cancer	1.3e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—lung cancer	1.3e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—MAPK3—lung cancer	1.3e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1A—lung cancer	1.29e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PTEN—lung cancer	1.29e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—BRAF—lung cancer	1.29e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—POMC—lung cancer	1.29e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—BRAF—lung cancer	1.29e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EP300—lung cancer	1.29e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6R—lung cancer	1.28e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—BRAF—lung cancer	1.27e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CREBBP—lung cancer	1.27e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6R—lung cancer	1.27e-05	0.000109	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CREBBP—lung cancer	1.27e-05	0.000109	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ENO1—lung cancer	1.27e-05	0.000109	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AKT1—lung cancer	1.26e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6R—lung cancer	1.26e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CREBBP—lung cancer	1.26e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CB—lung cancer	1.25e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—lung cancer	1.25e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SRC—lung cancer	1.25e-05	0.000108	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP1A1—lung cancer	1.25e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—lung cancer	1.25e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS2—lung cancer	1.24e-05	0.000107	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ERCC2—lung cancer	1.24e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—lung cancer	1.24e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EP300—lung cancer	1.23e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—lung cancer	1.22e-05	0.000105	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAP2K1—lung cancer	1.22e-05	0.000105	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAP2K1—lung cancer	1.21e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CD—lung cancer	1.21e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—STAT3—lung cancer	1.21e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CD—lung cancer	1.2e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NRAS—lung cancer	1.2e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAP2K1—lung cancer	1.2e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SRC—lung cancer	1.2e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	1.2e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	1.19e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CD—lung cancer	1.19e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—KRAS—lung cancer	1.18e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	1.18e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—KRAS—lung cancer	1.18e-05	0.000101	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—KRAS—lung cancer	1.17e-05	0.0001	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—lung cancer	1.17e-05	0.0001	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—STAT3—lung cancer	1.16e-05	9.94e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK3—lung cancer	1.15e-05	9.92e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NRAS—lung cancer	1.15e-05	9.92e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP2E1—lung cancer	1.14e-05	9.79e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NQO1—lung cancer	1.12e-05	9.68e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MYC—lung cancer	1.12e-05	9.65e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK3—lung cancer	1.1e-05	9.5e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—lung cancer	1.1e-05	9.43e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	1.09e-05	9.35e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTEN—lung cancer	1.08e-05	9.33e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	1.08e-05	9.32e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MDM2—lung cancer	1.08e-05	9.31e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MDM2—lung cancer	1.08e-05	9.28e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RAF1—lung cancer	1.08e-05	9.28e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RAF1—lung cancer	1.07e-05	9.25e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MYC—lung cancer	1.07e-05	9.24e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOA1—lung cancer	1.07e-05	9.23e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	1.07e-05	9.23e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MDM2—lung cancer	1.07e-05	9.19e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ERBB2—lung cancer	1.07e-05	9.18e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RAF1—lung cancer	1.06e-05	9.16e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ERBB2—lung cancer	1.06e-05	9.15e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ERBB2—lung cancer	1.05e-05	9.06e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MTOR—lung cancer	1.05e-05	9.06e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CB—lung cancer	1.05e-05	9.06e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—lung cancer	1.05e-05	9.03e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CB—lung cancer	1.05e-05	9.03e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MTOR—lung cancer	1.05e-05	9.03e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CB—lung cancer	1.04e-05	8.94e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MTOR—lung cancer	1.04e-05	8.94e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KRAS—lung cancer	1.04e-05	8.91e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—EP300—lung cancer	1.03e-05	8.9e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—STK11—lung cancer	1.01e-05	8.72e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL8—lung cancer	1.01e-05	8.7e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL8—lung cancer	1.01e-05	8.68e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—HRAS—lung cancer	1e-05	8.65e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—HRAS—lung cancer	1e-05	8.62e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL8—lung cancer	9.98e-06	8.59e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—HRAS—lung cancer	9.92e-06	8.54e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KRAS—lung cancer	9.92e-06	8.53e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CG—lung cancer	9.79e-06	8.42e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AKT1—lung cancer	9.77e-06	8.41e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AKT1—lung cancer	9.74e-06	8.38e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CASP3—lung cancer	9.68e-06	8.33e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL2—lung cancer	9.66e-06	8.32e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CASP3—lung cancer	9.65e-06	8.3e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AKT1—lung cancer	9.64e-06	8.3e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL2—lung cancer	9.63e-06	8.29e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—lung cancer	9.62e-06	8.28e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—lung cancer	9.59e-06	8.25e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CASP3—lung cancer	9.56e-06	8.22e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL2—lung cancer	9.54e-06	8.21e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CA—lung cancer	9.51e-06	8.19e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—lung cancer	9.49e-06	8.17e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCND1—lung cancer	9.42e-06	8.11e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—JUN—lung cancer	9.4e-06	8.09e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCND1—lung cancer	9.39e-06	8.08e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTP1—lung cancer	9.38e-06	8.07e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—JUN—lung cancer	9.37e-06	8.07e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—POMC—lung cancer	9.32e-06	8.02e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCND1—lung cancer	9.3e-06	8e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—JUN—lung cancer	9.28e-06	7.99e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—lung cancer	9.2e-06	7.92e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—lung cancer	9.15e-06	7.87e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CAT—lung cancer	9.13e-06	7.85e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—lung cancer	9.12e-06	7.85e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1A—lung cancer	9.11e-06	7.84e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CA—lung cancer	9.11e-06	7.84e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PTEN—lung cancer	9.09e-06	7.83e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1A—lung cancer	9.09e-06	7.82e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CREBBP—lung cancer	9.08e-06	7.81e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PTEN—lung cancer	9.06e-06	7.8e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—lung cancer	9.03e-06	7.77e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1A—lung cancer	9e-06	7.74e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PTEN—lung cancer	8.98e-06	7.73e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCB1—lung cancer	8.88e-06	7.64e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AKT1—lung cancer	8.87e-06	7.63e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AKT1—lung cancer	8.84e-06	7.61e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—lung cancer	8.81e-06	7.59e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HRAS—lung cancer	8.8e-06	7.58e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AKT1—lung cancer	8.76e-06	7.54e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—TYMS—lung cancer	8.72e-06	7.5e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EP300—lung cancer	8.67e-06	7.46e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EP300—lung cancer	8.64e-06	7.44e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTM1—lung cancer	8.62e-06	7.42e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CD—lung cancer	8.61e-06	7.41e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EP300—lung cancer	8.56e-06	7.37e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—lung cancer	8.5e-06	7.31e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SRC—lung cancer	8.43e-06	7.26e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HRAS—lung cancer	8.43e-06	7.25e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—lung cancer	8.43e-06	7.25e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SRC—lung cancer	8.41e-06	7.23e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SRC—lung cancer	8.32e-06	7.16e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—lung cancer	8.21e-06	7.07e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—lung cancer	8.19e-06	7.05e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1A1—lung cancer	8.17e-06	7.03e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—STAT3—lung cancer	8.13e-06	7e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NRAS—lung cancer	8.11e-06	6.98e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—lung cancer	8.11e-06	6.98e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—STAT3—lung cancer	8.11e-06	6.98e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ERCC2—lung cancer	8.1e-06	6.97e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NRAS—lung cancer	8.09e-06	6.96e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—lung cancer	8.07e-06	6.94e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—STAT3—lung cancer	8.03e-06	6.91e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NRAS—lung cancer	8.01e-06	6.89e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT1—lung cancer	7.77e-06	6.69e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK3—lung cancer	7.77e-06	6.69e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK3—lung cancer	7.75e-06	6.67e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK3—lung cancer	7.67e-06	6.6e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CA—lung cancer	7.65e-06	6.58e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MYC—lung cancer	7.56e-06	6.5e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MYC—lung cancer	7.53e-06	6.48e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CB—lung cancer	7.5e-06	6.46e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MYC—lung cancer	7.46e-06	6.42e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT1—lung cancer	7.44e-06	6.41e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS2—lung cancer	7.43e-06	6.4e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—lung cancer	7.39e-06	6.36e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—lung cancer	7.37e-06	6.34e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—lung cancer	7.3e-06	6.28e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOA1—lung cancer	7.01e-06	6.03e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KRAS—lung cancer	6.98e-06	6.01e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KRAS—lung cancer	6.96e-06	5.99e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KRAS—lung cancer	6.89e-06	5.93e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTEN—lung cancer	6.48e-06	5.58e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CA—lung cancer	6.42e-06	5.52e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CG—lung cancer	6.4e-06	5.51e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CA—lung cancer	6.39e-06	5.5e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CA—lung cancer	6.33e-06	5.45e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AKT1—lung cancer	6.25e-06	5.38e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—lung cancer	6.21e-06	5.34e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—lung cancer	6.19e-06	5.32e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—EP300—lung cancer	6.18e-06	5.32e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—lung cancer	6.13e-06	5.27e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—POMC—lung cancer	6.09e-06	5.24e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HRAS—lung cancer	5.94e-06	5.11e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CREBBP—lung cancer	5.93e-06	5.11e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HRAS—lung cancer	5.92e-06	5.09e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HRAS—lung cancer	5.86e-06	5.04e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—lung cancer	5.68e-06	4.89e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—lung cancer	5.66e-06	4.87e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CD—lung cancer	5.63e-06	4.84e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—lung cancer	5.61e-06	4.83e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—lung cancer	5.55e-06	4.78e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT1—lung cancer	5.24e-06	4.51e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT1—lung cancer	5.22e-06	4.5e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT1—lung cancer	5.17e-06	4.45e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CB—lung cancer	4.9e-06	4.22e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS2—lung cancer	4.86e-06	4.18e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CA—lung cancer	4.57e-06	3.94e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTEN—lung cancer	4.24e-06	3.65e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—EP300—lung cancer	4.04e-06	3.48e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AKT1—lung cancer	3.74e-06	3.21e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CA—lung cancer	2.99e-06	2.57e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AKT1—lung cancer	2.44e-06	2.1e-05	CbGpPWpGaD
